Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following...
Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO Dupixent est le premier médicament biologique approuvé aux États-Unis...
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled...
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent approved in the US as the first-ever biologic medicine for patients with...
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations...
Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on...
Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la...
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval...
Press Release: Availability of the Q3 2024 Aide mémoire Availability of the Q3 2024 Aide mémoire Paris, France – September 26, 2024. Sanofi announced today that its Q3 2024 Aide mémoire is...
Availability of the Q3 2024 Aide mémoire Paris, France – September 26, 2024. Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website:...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1 | -0.0982125319191 | 101.82 | 104.46 | 99.87 | 1579257 | 102.55555711 | DE |
4 | -2.66 | -2.54838091588 | 104.38 | 106.08 | 99.87 | 1588529 | 103.37371511 | DE |
12 | 7.25 | 7.67439398751 | 94.47 | 106.14 | 90.73 | 1452055 | 99.61514113 | DE |
26 | 12.91 | 14.536651278 | 88.81 | 106.14 | 85.07 | 1477274 | 94.24719016 | DE |
52 | -0.2 | -0.196232339089 | 101.92 | 106.14 | 80.6 | 1494037 | 91.84854933 | DE |
156 | 18.12 | 21.6746411483 | 83.6 | 106.66 | 76.45 | 1772292 | 92.11570567 | DE |
260 | 20.55 | 25.3172354318 | 81.17 | 106.66 | 67.65 | 1968133 | 88.97024844 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales